SavedAdd your journal

Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2006 / Cilt: 16 - Sayı: 3

Hepatitis B and C seroprevalence in cancer patients: A control study

Kanserli hastalarda hepatit B ve C sıklığı: Vaka kontrol çalışması

Güngör UTKAN
Alpay AZAP
Sadık MUALLAOĞLU
Saadet TOKLUOĞLU
Ayşe G. DURNALI
Ülkü Y. ARSLAN
MURAT KOÇER
Gökhan ÇELENKOĞLU
Hakan AKBULUT
Necati ALKIŞ
Pages
103–107
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The difference seen in patients with cancer highlights importance of screening for pre-treatment hepatitis markers in this patient group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:During the diagnosis and treatment, patients with cancer may either become hepatitis carrier due to one or more reasons, or subject to the risk of hepatitis reactivation as a result of immunosuppressive treatment.
📊
Key Findings & Data:In Group A, prevalence of HBs Ag, Anti-HBs (AHBs) and Anti-HCV (AHCV) was measured as %4.8, %14, %2.8 respectively while the same rates were measured as %1.2, %42.4, %1.4 in the Group B.
💡
Conclusion & Impact:The difference seen in patients with cancer highlights importance of screening for pre-treatment hepatitis markers in this patient group.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hepatit B yüzey antijenleri · Hepatit C antikorları · Yaygınlık

Abstract

During the diagnosis and treatment, patients with cancer may either become hepatitis carrier due to one or more reasons, or subject to the risk of hepatitis reactivation as a result of immunosuppressive treatment. This study aims to determine seroprevalence of Hepatitis B (HBV) or Hepatitis C (HCV) in adult patients with cancer, and compare them with patients who were admitted to hospital for non-cancer reasons. This study includes five-hundred patients who have been recently diagnosed with cancer (Group A) and five-hundred patients who were admitted to hospital for other reasons except for cancer (Group B). In Group A, prevalence of HBs Ag, Anti-HBs (AHBs) and Anti-HCV (AHCV) was measured as %4.8, %14, %2.8 respectively while the same rates were measured as %1.2, %42.4, %1.4 in the Group B. When the Group A was compared with the Group B, hepatitis carrier state (HBV or HCV) and HBs carrier state were more common in patients with cancer while a meaningful difference was not seen in regard to HCV. The difference seen in patients with cancer highlights importance of screening for pre-treatment hepatitis markers in this patient group.

Özet

Kanserli hastalar, tanı ve takipleri süresince; bir veya birden fazla nedenle hepatit taşıyıcılığı veya immunsupresif tedavi sonucunda hepatit reaktivasyonu riskine maruz kalabilmektedir. Çalışmamızda, erişkin kanser hastalarında hepatit B (HBV) veya C (HCV) seroprevalansının saptanması ve kanser dışı nedenlerle hastaneye başvuran hastalarla karşılaştırılması amaçlanmıştır. Beş yüz yeni tanı kanserli hasta (Grup A) ve beş yüz kanser dışı nedenle hastaneye başvurmuş hasta (Grup B) çalışmaya alınmıştır. Grup A da HBs Ag, Anti-HBs (AHBs) ve Anti-HCV (AHCV) prevalansı sırasıyla %4.8, %14, %2.8 olarak bulunmuştur. Grup B de ise bu oranlar %1.2, %42.4, %1.4 olarak saptanmıştır. Grup A ve B karşılaştırıldığında hepatit taşıyıcılığı (HBV veya HCV) ve HBs taşıyıcılığı kanserli hastalarda daha sık olarak gözlenirken HCV açısından anlamlı fark gözlenmedi. Kanserli hastalarda gözlenen bu farklılık, bu hasta grubunda tedavi öncesi hepatit markırlarının bakılmasının önemini desteklemektedir.

🔖

Cite This Article

UTKAN, G., AZAP, A., MUALLAOĞLU, S., TOKLUOĞLU, S., DURNALI, A. G., ARSLAN, Ü. Y., KOÇER, M., ÇELENKOĞLU, G., AKBULUT, H., ALKIŞ, N. (2006). Hepatitis B and C seroprevalence in cancer patients: A control study. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 16 - Sayı: 3, 103–107. https://ajindex.com/articles/323241

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Ockner RK. Acute viral hepatitis. In Bennett C, Plum F (eds): Cecil Textbook of Medicine, 20 th edition. Philadelphia, PA: Lippincott Williams & Wilkins 1996; 765-768
  2. Yeo W, Chan PK, Hui P, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 70:553-561, 2003
  3. Vassiliadis T, Garipidou V, Tziomalos K, et al. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy- A prospective case series. Am J Hematol 80:197-203, 2005
  4. Idilman R, Arat M, Soydan E, et al. J Viral Hepat. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 11:141-147, 2004
  5. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22: 927-934, 2004
  6. Yeo W, Chan PK, Zhong S, Ho WM, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62: 299-307, 2000
  7. Rossi G, Pelizzari A, Motta M, et al. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 115: 58-62, 2001
  8. Steinberg JL, Yeo W, Zhong S, et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/ core mutations may play an important role. J Med Virol 60: 249-255, 2000
  9. Balık İ. Hepatit B epidemiyolojisi. IN: Kılıcturgay A (ed). Viral Hepatit 94. İstanbul; Nobel Tıp Kitabevi, 1994, 91-101
  10. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 34:1-3, 2005
  11. Şahin Y, Aydın D. Altı yaş ve altı çocuklarda Hepatit B seroprevalansı. Fırat Tıp Dergisi 10: 169-172, 2005
  12. Baykan M, Ertuğrul Ö. Türkiye’de HBV ve HCV enfeksiyonlarının durumu. Genel Tıp Dergisi 11: 89-92, 2001
  13. RK Ockner. Acute viral hepatitis. In Gill JC Bennett, F Plum (eds): Cecil Textbook of Medicine, 20 th edition, Philedelphia, PA: WB Saunders Company, 1996; 766
  14. Balık İ. Çeşitli gruplarda Hepatit C virus antikorlarının prevalansı. Turk J Gastroenteheptol 1: 55-58, 1990
  15. Ozdemir O, Arda K